Related Experiment Video
Updated: Aug 18, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
[Patent foramen ovale--demographic, clinical and echocardiographic characteristics]
Marek Maciejewski1, Marzenna Zielińska, Halina Bolinska
1Klinika Kardiologii I Katedry Kardiologii i Kardiochirurgii Uniwersytetu Medycznego, Lodzi. marekmaciejewski@poczta.fm
Insights
Patent foramen ovale (PFO) is a risk factor for systemic embolism/transient ischemic attack, but only when it is the sole cardiac abnormality. Minimal flow through PFO is typical in these cases.
Area of Science:
- Cardiology
- Vascular Medicine
- Embryology
Background:
- Patent foramen ovale (PFO) is the most common persistent fetal circulatory abnormality.
- PFO is associated with an increased risk of paradoxical embolism.
Purpose of the Study:
- To determine the incidence and characteristics of PFO.
- To evaluate PFO as a risk factor for paradoxical embolism.
Main Methods:
- Retrospective analysis of 945 patients undergoing TEE (transesophageal echocardiography) between 1998-2002.
- Patients were categorized based on PFO presence and history of systemic embolism (SE) or transient ischemic attack (TIA).
- Subgroup analysis compared patients with isolated PFO versus those with PFO and other cardiac/aortic diseases.
Main Results:
- PFO was diagnosed in 57 patients (6%).
- The incidence of SE/TIA was significantly higher in patients with isolated PFO (xPFO(+)) compared to controls without PFO (xPFO(-)).
- Higher shunt intensity was observed in patients with PFO and coexisting heart disease (yPFO(+)) compared to isolated PFO (xPFO(+)).
Conclusions:
- PFO is a risk factor for SE/TIA exclusively in patients with isolated PFO.
- Flow through PFO in isolated cases is generally minimal.
- Coexisting heart pathology can lead to significant right-to-left or left-to-right shunting through a PFO.
Unlabelled:
Patent foramen ovale (PFO) represents the most common persistent abnormality of fetal origin. The aim of the study was to analyze the incidence and characteristics of PFO and to assess PFO as the risk factor of paradoxical embolism. 945 consecutive pts (442F and 503M aged 13-85, mean 53.02 +/- 14.42 years) in whom TEE was performed and flow through PFO was detected in basal conditions (colour-Doppler) and/or during provocation (Valsalva/cough manoeuvre) with contrast (saline infusion) at the period 1998-2002 was retrospectively analyzed. 183 pt had a history of systemic embolisation (SE) or transient ischemic attack (TIA). PFO was diagnosed [PFO(+)] in 57 pts (6%)-22F, 35M aged 14-77 years, mean 52.44 +/- 14.84 years. 888 pts without PFO [PFO(-)] created a control group. Two subgroups were analyzed in the study group: xPFO(+) - 28 pts with PFO as the only abnormality, yPFO(+) - 29 pts with PFO and other heart/aortic disease. Similarly, in the control group two subgroups were analysed: xPFO(-) - pts with normal TEE and negative history of heart/aortic disease and yPFO(-) - pts without PFO but with other heart/aortic disease. Aneurysmal formation of interatrial septum was detected in 24 pts, and in 6 pts it coexisted with PFO. The intensity of shunt was significantly higher in yPFO(+) than in xPFO(+) group. In 5 pts permanent shunt through PFO at the basal stage was observed (4 pts with significant regurgitation of the atrio-ventricular valves and one patient with tricuspid stenosis). Percentage of pts with the history of SE/TIA was significantly higher in group xPFO(+) than in xPFO(-) (p < 0.01).
Conclusions:
(1) PFO is a risk factor of SE/TIA only in group xPFO(+). (2) Flow through PFO in group xPFO(+) is generally minimal. (3) In case of coexisting heart pathology PFO may provoke significant right-to-left or even left-to-right shunt.
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis I: Introduction
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Mitral Regurgitation I: Introduction

